Menu Search
Equities

Aurora Spine Corp

ASAPF:QBB

Aurora Spine Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.19
  • Today's Change-0.02 / -9.52%
  • Shares traded16.00k
  • 1 Year change-23.69%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 20:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurora Spine Corporation is a designer and manufacturer of medical devices. The Company is engaged in the development and distribution of minimally invasive, interspinous fusion systems and devices. Its product line includes implants, surgical tools and biologics. Its implants include Cervical Products, Thoraco-Lumbar Products, and SI joint products. The surgical tools include Anterior Disc Prep, Posterior Disc Prep and Compass 4D Retractor System. The biologics consist of ZIP Graft and SiLO Si-Fusion. The Company is focused on DEXA technology, which opens up treatment for osteoporotic patients. It offers DEXA-C Cervical Implants Featuring Visual Density Markers, and DEXA -L Standalone Anterior Lumbar Interbody Fusion System.

  • Revenue in CAD (TTM)19.87m
  • Net income in CAD-2.30m
  • Incorporated2013
  • Employees13.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.